Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

4(66.7%)

N/A

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 3(4)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07272122Phase 3Not Yet Recruiting

Reducing Filth Fly Populations and Transmission of Diarrhoeal Pathogens in Harsh Settings

Role: lead

NCT07145736Phase 4Recruiting

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

Role: collaborator

NCT06917040Phase 3Completed

Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria

Role: lead

NCT06179732Phase 3Completed

Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities

Role: lead

NCT02448745Not ApplicableCompleted

Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL)

Role: lead

NCT01456858Phase 3Completed

Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies

Role: lead

All 6 trials loaded